Deep Track Capital, LP Q3 2023 significant ownership

Add to watchlist

Deep Track Capital, LP is required to file a 13D/G report to the SEC when the ownership of a company's total stock issue exceeds 5%.

Deep Track Capital, LP Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Orchard Therapeutics plcMarch 20, 202319,125,15010.0%
ARDELYX, INC.Sold outFebruary 14, 202300.0%
ASSEMBLY BIOSCIENCES, INC.February 14, 20231,833,4373.8%
Aurinia Pharmaceuticals Inc.February 14, 2023324,2380.2%
CHINOOK THERAPEUTICS, INC.February 14, 20233,000,0004.7%
Forma Therapeutics Holdings, Inc.Sold outFebruary 14, 202300.0%
Global Blood Therapeutics, Inc.Sold outFebruary 14, 202300.0%
HOOKIPA Pharma Inc.February 14, 20231,240,3692.4%
KalVista Pharmaceuticals, Inc.Sold outFebruary 14, 202300.0%
Keros Therapeutics, Inc.Sold outFebruary 14, 202300.0%
Kura Oncology, Inc.Sold outFebruary 14, 202300.0%
MADRIGAL PHARMACEUTICALS, INC.Sold outFebruary 14, 202300.0%
Magenta Therapeutics, Inc.February 14, 20233,000,0005.0%
Nkarta, Inc.February 14, 20231,354,2002.8%
Nuvation Bio Inc.February 14, 20238,221,1883.8%
Passage BIO, Inc.Sold outFebruary 14, 202300.0%
Tricida, Inc.February 14, 20234,666,6667.4%
Syros Pharmaceuticals, Inc.September 19, 2022699,28110.0%
AVROBIO, Inc.February 14, 20221,050,1322.4%
Crinetics Pharmaceuticals, Inc.February 14, 20221,900,0004.0%

Compare quarters

Export Deep Track Capital, LP's holdings

CSVXLS